Literature DB >> 11755947

Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease.

T Matsumoto1, M Shima, K Fukuda, K Nogami, J C Giddings, T Murakami, I Tanaka, A Yoshioka.   

Abstract

The development of a factor VIII autoantibody results in a severe hemorrhagic diathesis known as acquired hemophilia A. Underlying pathologies, such as autoimmune disease or chronic inflammatory disease, are observed in about half of the patients. We have investigated a total of 16 cases with acquired hemophilia A and divided the patients into two groups according to the presence or absence of other clinical conditions. Group A comprised nine cases with no detectable associated pathology. Group B consisted of seven cases with other clinical diagnoses. Significant levels of factor VIII activity (FVIII:C) and factor VIII antigen (FVIII:Ag) were detected in Group A and the pattern of FVIII:C inactivation was characteristic of Type 2 inhibitors. In contrast, no FVIII:C was detected in Group B and, in five of seven cases, the inhibitory pattern was Type 1. IgG(4) antibody subclass specificity was dominant in both groups. IgG1 antibody reactivity was higher in Group B than in Group A. Our results suggested a close relationship between the presence of underlying disease and immunological and coagulation characteristics in acquired hemophilia A.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755947     DOI: 10.1016/s0049-3848(01)00385-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.

Authors:  Massimo Franchini; Giancarlo Castaman; Antonio Coppola; Cristina Santoro; Ezio Zanon; Giovanni Di Minno; Massimo Morfini; Elena Santagostino; Angiola Rocino
Journal:  Blood Transfus       Date:  2015-06-24       Impact factor: 3.443

2.  First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin.

Authors:  Masahiro Takeyama; Keiji Nogami; Takahiro Kajimoto; Kenichi Ogiwara; Tomoko Matsumoto; Midori Shima
Journal:  Int J Hematol       Date:  2017-06-08       Impact factor: 2.490

3.  Management of rare acquired bleeding disorders.

Authors:  Marzia Menegatti; Eugenia Biguzzi; Flora Peyvandi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  [Acute airway obstruction in acquired hemophilia A].

Authors:  J B Weise; H Plendl; F Gieseler; S Preuss; S Maune
Journal:  HNO       Date:  2005-05       Impact factor: 1.284

Review 5.  Characterization of factor VIII inhibitors.

Authors:  Midori Shima
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

6.  [Spontaneous hematoma and hip pain in a 65-year old patient].

Authors:  C Sucker; S Korfmacher; M Papp-Váry; C Grieser; H Riess
Journal:  Internist (Berl)       Date:  2012-10       Impact factor: 0.743

7.  Acquired haemophilia A associated with autoimmune thyroiditis: a case report.

Authors:  Upul G P Pathirana; Nirmali Gunawardena; Hiranya Abeysinghe; Hannah Charlotte Copley; M G Dhammika Somarathne
Journal:  J Med Case Rep       Date:  2014-12-29

Review 8.  Acquired Hemophilia A in IgG4-Related Disease: Case Report, Immunopathogenic Study, and Review of the Literature.

Authors:  Sébastien Sanges; Emmanuelle Jeanpierre; Benjamin Lopez; Jules Russick; Sandrine Delignat; Benjamin Carpentier; Romain Dubois; Sylvain Dubucquoi; Thomas Guerrier; Éric Hachulla; Pierre-Yves Hatron; Camille Paris; Sophie Susen; David Launay; Sébastien Lacroix-Desmazes; Louis Terriou
Journal:  Front Immunol       Date:  2020-12-18       Impact factor: 7.561

9.  Perioperative Bypassing Agent Therapy for Pulmonary Pleomorphic Carcinoma with Acquired Hemophilia.

Authors:  Takashi Sakai; Yoko Azuma; Atsushi Sano; Sota Sadamoto; Naobumi Tochigi; Daisuke Nagase; Akira Iyoda
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-01-20       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.